Advertisement

Journal of Neurology

, Volume 260, Issue 3, pp 701–713 | Cite as

Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system

  • Dirk DresslerEmail author
Review

Abstract

Botulinum toxin (BoNT) has gained widespread use for the treatment of overactive muscles, overactive exocrine glands and, most recently, non-muscular pain conditions. Autonomic conditions treated with BoNT include achalasia, gastroparesis, sphincter of Oddi spasms, and unspecific esophageal spasms in gastroenterology and prostate disorders in urology. BoNT’s use for autonomic conditions related to neurology includes various forms of bladder dysfunction (detrusor sphincter dyssynergia, idiopathic detrusor overactivity, neurogenic detrusor overactivity, urinary retention and bladder pain syndrome), pelvic floor disorders (pelvic floor spasms and anal fissures), hyperhidrosis (axillary, palmar, and plantar hyperhidrosis, diffuse sweating, Frey’s syndrome) and hypersalivation (hypersalivation in Parkinsonian syndromes, motor neuron disease, neuroleptic use, and cerebral palsy). Hyperhidrosis, hypersalivation, some forms of bladder dysfunction and pelvic floor disorders can easily be treated by neurologists. Most bladder dysfunctions require cooperation with urology departments.

Keywords

Botulinum toxin Therapeutic use Autonomic disorders Neurology 

Notes

Conflicts of interest

DD receives compensation for consultancy work for Allergan, Ipsen, Eisai/Solstice and Merz. He is shareholder of Allergan.

References

  1. 1.
    Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  2. 2.
    Qerama E, Fuglsang-Frederiksen A, Jensen TS (2010) The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 23:602–610PubMedCrossRefGoogle Scholar
  3. 3.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922PubMedGoogle Scholar
  4. 4.
    Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71:24–26PubMedGoogle Scholar
  5. 5.
    Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029PubMedCrossRefGoogle Scholar
  6. 6.
    Beleggia F, Beccia E, Imbriani E, Basciani M, Intiso D, Cioffi R et al (1997) The use of type A botulin toxin in the treatment of detrusor-sphincter dyssynergia. Arch Ital Urol Androl 69(Suppl 1):61–63PubMedGoogle Scholar
  7. 7.
    Petit H, Wiart L, Gaujard E, Le Breton F, Ferrière JM, Lagueny A (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36:91–94PubMedCrossRefGoogle Scholar
  8. 8.
    Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79:715–717PubMedCrossRefGoogle Scholar
  9. 9.
    de Sèze M, Petit H, Gallien P, de Sèze MP, Joseph PA, Mazaux JM et al (2002) Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62PubMedCrossRefGoogle Scholar
  10. 10.
    Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E (2005) Placebo-controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76:1670–1676PubMedCrossRefGoogle Scholar
  11. 11.
    Chen SL, Bih LI, Chen GD, Huang YH, You YH, Lew HL (2010) Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. Arch Phys Med Rehabil 91:340–344PubMedCrossRefGoogle Scholar
  12. 12.
    Schurch B, Hodler J, Rodic B (1997) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 63:474–476PubMedCrossRefGoogle Scholar
  13. 13.
    Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL (2009) Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil 90:832–836PubMedCrossRefGoogle Scholar
  14. 14.
    Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRefGoogle Scholar
  15. 15.
    Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96:848–852PubMedCrossRefGoogle Scholar
  16. 16.
    Sahai A (2006) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 97:413PubMedCrossRefGoogle Scholar
  17. 17.
    Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo-controlled trial. J Urol 177:2231–2236PubMedCrossRefGoogle Scholar
  18. 18.
    Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100:1302–1306PubMedCrossRefGoogle Scholar
  19. 19.
    Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B (2008) Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 19:905–909PubMedCrossRefGoogle Scholar
  20. 20.
    Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217–222PubMedCrossRefGoogle Scholar
  21. 21.
    Lie KY, Wong MY, Ng LG (2010) Botulinum toxin a for idiopathic detrusor overactivity. Ann Acad Med Singapore 39:714–715PubMedGoogle Scholar
  22. 22.
    Gomez CS, Kanagarajah P, Gousse A (2010) The use of botulinum toxin a in idiopathic overactive bladder syndrome. Curr Urol Rep 11:353–359PubMedCrossRefGoogle Scholar
  23. 23.
    Sahai A, Dowson C, Khan MS, GKT Botulinum Study Group (2010) Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75:552–558PubMedCrossRefGoogle Scholar
  24. 24.
    Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ et al (2005) Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo-controlled, crossover trial. Urol 174:1873–1877CrossRefGoogle Scholar
  25. 25.
    Sahai A, Dowson C, Khan MS, Dasgupta P (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509–1515PubMedCrossRefGoogle Scholar
  26. 26.
    Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR et al (2007) Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 69:69–73PubMedCrossRefGoogle Scholar
  27. 27.
    Kuo HC, Liao CH, Chung SD (2010) Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 8:919–926CrossRefGoogle Scholar
  28. 28.
    Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697CrossRefGoogle Scholar
  29. 29.
    Kenelly MJ, Kang J (2003) Botulinum-A toxin injections as a treatment fro refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 8:46–53CrossRefGoogle Scholar
  30. 30.
    Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79–87PubMedGoogle Scholar
  31. 31.
    Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRefGoogle Scholar
  32. 32.
    Bagi P, Biering-Sørensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:495–498PubMedCrossRefGoogle Scholar
  33. 33.
    Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 174:196–200PubMedCrossRefGoogle Scholar
  34. 34.
    Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH (2005) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25:110–115CrossRefGoogle Scholar
  35. 35.
    Grosse J, Kramer G, Stöhrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRefGoogle Scholar
  36. 36.
    Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:37–41PubMedCrossRefGoogle Scholar
  37. 37.
    Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J (2005) Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 12:2543–2546PubMedGoogle Scholar
  38. 38.
    Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24:231–236PubMedCrossRefGoogle Scholar
  39. 39.
    Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989PubMedCrossRefGoogle Scholar
  40. 40.
    Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:232–236PubMedCrossRefGoogle Scholar
  41. 41.
    Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030–1034PubMedCrossRefGoogle Scholar
  42. 42.
    Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535PubMedCrossRefGoogle Scholar
  43. 43.
    Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193–1197PubMedCrossRefGoogle Scholar
  44. 44.
    Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C et al (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41:335–340PubMedCrossRefGoogle Scholar
  45. 45.
    Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH (2002) Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59:325–327PubMedCrossRefGoogle Scholar
  46. 46.
    Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH (2003) Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139–143PubMedCrossRefGoogle Scholar
  47. 47.
    Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848PubMedCrossRefGoogle Scholar
  48. 48.
    Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870PubMedCrossRefGoogle Scholar
  49. 49.
    Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH et al (2006) Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68:1091–1096PubMedCrossRefGoogle Scholar
  50. 50.
    Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke E (2006) The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176:328–330PubMedCrossRefGoogle Scholar
  51. 51.
    Akbar M, Abel R, Seyler TM, Bedke J, Haferkamp A, Gerner HJ et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639–645PubMedCrossRefGoogle Scholar
  52. 52.
    Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165:1107–1110PubMedCrossRefGoogle Scholar
  53. 53.
    Kuo HC (2003) Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61:550–554PubMedCrossRefGoogle Scholar
  54. 54.
    Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG (1992) Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70:387–389PubMedCrossRefGoogle Scholar
  55. 55.
    Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871–875PubMedCrossRefGoogle Scholar
  56. 56.
    Kuo HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75:170–174PubMedCrossRefGoogle Scholar
  57. 57.
    Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704–709PubMedCrossRefGoogle Scholar
  58. 58.
    Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70:463–468PubMedCrossRefGoogle Scholar
  59. 59.
    Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 179:1031–1034PubMedCrossRefGoogle Scholar
  60. 60.
    Brin MF, Vapnek JM (1997) Treatment of vaginismus with botulinum toxin injections. Lancet 349:252–253PubMedCrossRefGoogle Scholar
  61. 61.
    Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G (2006) Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 51:635–641PubMedGoogle Scholar
  62. 62.
    Gunter J, Brewer A, Tawfik O (2004) Botulinum toxin A for vulvodynia: a case report. J Pain 5:238–240PubMedCrossRefGoogle Scholar
  63. 63.
    Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG (2004) Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44:46–50PubMedCrossRefGoogle Scholar
  64. 64.
    Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG (2005) The use of botulinum toxin type A (Botox) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 112:247–249PubMedCrossRefGoogle Scholar
  65. 65.
    Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108:915–923PubMedCrossRefGoogle Scholar
  66. 66.
    Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A (2000) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43:376–380PubMedCrossRefGoogle Scholar
  67. 67.
    Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 8613:714–717CrossRefGoogle Scholar
  68. 68.
    Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39:1107–1111PubMedCrossRefGoogle Scholar
  69. 69.
    Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S et al (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44:1821–1826PubMedCrossRefGoogle Scholar
  70. 70.
    Jost WH, Schimrigk K (1994) Therapy of anal fissure using botulin toxin. Dis Colon Rectum 37:1321–1324PubMedCrossRefGoogle Scholar
  71. 71.
    Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A (1994) Botulinum toxin for chronic anal fissure. Lancet 344(8930):1127–1128PubMedCrossRefGoogle Scholar
  72. 72.
    Tranqui P, Trottier DC, Victor C, Freeman JB (2006) Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin. Can J Surg 49:41–55PubMedGoogle Scholar
  73. 73.
    Festen S, Gisbertz SS, van Schaagen F, Gerhards MF (2009) Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure. Br J Surg 96:1393–1399PubMedCrossRefGoogle Scholar
  74. 74.
    Wollina U (2008) Pharmacological sphincterotomy for chronic anal fissures by botulinum toxin A. J Cutan Aesthet Surg 1:58–63PubMedCrossRefGoogle Scholar
  75. 75.
    Strutton DR, Kowalski JW, Glaser DA, Stang PE (2004) US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51:241–248PubMedCrossRefGoogle Scholar
  76. 76.
    Bushara KO, Park DM, Jones JC, Schutta HS (1996) Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 21:276–278PubMedCrossRefGoogle Scholar
  77. 77.
    Heckmann M, Ceballos-Baumann AO, Plewig G (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:48893CrossRefGoogle Scholar
  78. 78.
    Naumann M, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo-controlled trial. BMJ 323:596–599CrossRefGoogle Scholar
  79. 79.
    Naumann M, Lowe NJ, Kumar CR, on behalf of the BOTOX Hyperhidrosis Clinical Study Group (2003) Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139:731–736PubMedCrossRefGoogle Scholar
  80. 80.
    Lowe PL, Cerdan-Sanz S, Lowe NJ (2003) Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis; efficacy and duration with repeated treatments. Dermatol Surg 29:5458CrossRefGoogle Scholar
  81. 81.
    Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY et al (2007) Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 56:604–611PubMedCrossRefGoogle Scholar
  82. 82.
    Dressler D (2010) Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm 117:317–319PubMedCrossRefGoogle Scholar
  83. 83.
    Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K (1997) Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136:548–552PubMedCrossRefGoogle Scholar
  84. 84.
    Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K et al (1999) A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 140:677–680PubMedCrossRefGoogle Scholar
  85. 85.
    Schnider P, Moraru E, Kittler H, Binder M, Kranz G, Voller B et al (2001) Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol 145:289–293PubMedCrossRefGoogle Scholar
  86. 86.
    Salmanpoor R, Rahmanian MJ (2002) Treatment of axillary hyperhidrosis with botulinum-A toxin. Int J Dermatol 41:428–430PubMedCrossRefGoogle Scholar
  87. 87.
    Heckmann M, Hyperhidrosis Study Group (2005) Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141:1255–1259PubMedCrossRefGoogle Scholar
  88. 88.
    Moffat CE, Hayes WG, Nyamekye IK (2009) Durability of botulinum toxin treatment for axillary hyperhidrosis. Eur J Vasc Endovasc Surg 38:188–191PubMedCrossRefGoogle Scholar
  89. 89.
    Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732PubMedCrossRefGoogle Scholar
  90. 90.
    Nelson L, Bachoo P, Holmes J (2005) Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plast Surg 58:228–232PubMedCrossRefGoogle Scholar
  91. 91.
    Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38PubMedCrossRefGoogle Scholar
  92. 92.
    Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS et al (2008) Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1707–1714PubMedCrossRefGoogle Scholar
  93. 93.
    Naumann M, Flachenecker P, Bröcker EB, Toyka KV, Reiners K (1997) Botulinum toxin for palmar hyperhidrosis. Lancet 349:252PubMedCrossRefGoogle Scholar
  94. 94.
    Shelley WB, Talanin NY, Shelley ED (1998) Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 38:227–229PubMedCrossRefGoogle Scholar
  95. 95.
    Naver H, Swartling C, Aquilonius SM (2000) Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 7:55–62PubMedCrossRefGoogle Scholar
  96. 96.
    Solomon BA, Hayman R (2000) Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42:1026–1029PubMedCrossRefGoogle Scholar
  97. 97.
    Vadoud-Seyedi J, Heenen M, Simonart T (2001) Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature. Dermatology 203:318–321PubMedCrossRefGoogle Scholar
  98. 98.
    Saadia D, Voustianiouk A, Wang AK, Kaufmann H (2001) Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 57:2095–2099PubMedCrossRefGoogle Scholar
  99. 99.
    Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S (2002) Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28:822–827PubMedCrossRefGoogle Scholar
  100. 100.
    Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM (2003) A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 149:1041–1045PubMedCrossRefGoogle Scholar
  101. 101.
    Pérez-Bernal AM, Avalos-Peralta P, Moreno-Ramírez D, Camacho F (2005) Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience. J Cosmet Dermatol 4:163–166PubMedCrossRefGoogle Scholar
  102. 102.
    Yamashita N, Shimizu H, Kawada M, Yanagishita T, Watanabe D, Tamada Y (2008) Local injection of botulinum toxin A for palmar hyperhidrosis: usefulness and efficacy in relation to severity. J Dermatol 35:325–329PubMedCrossRefGoogle Scholar
  103. 103.
    Dressler D (2010) Routine use of Xeomin in patients previously treated with Botox: long-term results. Eur J Neurol 16(Suppl 2):2–5Google Scholar
  104. 104.
    Baumann LS, Halem ML (2003) Systemic adverse effects after botulinum toxin type B (MYOBLOC) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139:226–227PubMedGoogle Scholar
  105. 105.
    Baumann L, Slezinger A, Halem M, Vujevich J, Mallin K, Charles C et al (2005) Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of MYOBLOC (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 31:263–270PubMedCrossRefGoogle Scholar
  106. 106.
    Baumann L, Frankel S, Welsh E, Halem M (2003) Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. Dermatol Surg 29:1057–1059PubMedCrossRefGoogle Scholar
  107. 107.
    Smith KC, Comite SL, Storwick GS (2007) Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 33:S88–S91PubMedCrossRefGoogle Scholar
  108. 108.
    Lim EC, Seet RC (2007) Another injection-free method to effect analgesia when injecting botulinum toxin for palmar hyperhidrosis: cryoanalgesia. Dermatol Online J 13:25PubMedGoogle Scholar
  109. 109.
    Richards RN (2009) Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 13:253–256PubMedGoogle Scholar
  110. 110.
    Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A (2004) Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 51:345–348PubMedCrossRefGoogle Scholar
  111. 111.
    Blaheta HJ, Vollert B, Zuder D, Rassner G (2004) Intravenous regional anesthesia (Bier’s block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol Surg 28:666–671CrossRefGoogle Scholar
  112. 112.
    Patel R, Halem M, Zaiac M (2009) The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhidrosis with botulinum toxin injections. J Drugs Dermatol 8:948–951PubMedGoogle Scholar
  113. 113.
    Bosdotter Enroth S, Rystedt A, Covaciu L, Hymnelius K, Rystedt E, Nyberg R et al (2010) Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis. J Am Acad Dermatol 63:466–474PubMedCrossRefGoogle Scholar
  114. 114.
    Davarian S, Kalantari KK, Rezasoltani A, Rahimi A (2008) Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol 49:75–79PubMedCrossRefGoogle Scholar
  115. 115.
    Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134:301–304PubMedCrossRefGoogle Scholar
  116. 116.
    Sevim S, Dogu O, Kaleagasi H (2002) Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg 102:167–170PubMedGoogle Scholar
  117. 117.
    Vadoud-Seyedi J (2004) Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 43:969–971PubMedCrossRefGoogle Scholar
  118. 118.
    Campanati A, Bernardini ML, Gesuita R, Offidani A (2007) Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 17:52–54PubMedGoogle Scholar
  119. 119.
    Kinkelin I, Hund M, Naumann M, Hamm H (2000) Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 143:824–827PubMedCrossRefGoogle Scholar
  120. 120.
    Santana-Rodríguez N, Clavo-Varas B, Ponce-González MA, Jarabo-Sarceda JR, Pérez-Alonso D, Ruiz-Caballero JA et al (2010) Primary frontal hyperhidrosis successfully treated with low doses of botulinum toxin A as a useful alternative to surgical treatment. J Dermatolog Treat [Epub ahead of print]Google Scholar
  121. 121.
    Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K (2007) Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33:924–927PubMedCrossRefGoogle Scholar
  122. 122.
    Schulze-Bonhage A, Schroder M, Ferbert A (1996) Botulinum toxin in the therapy of gustatory sweating. J Neurol 243:143–146PubMedCrossRefGoogle Scholar
  123. 123.
    Bjerkhoel A, Trobbe O (1997) Frey’s syndrome: treatment with botulinum toxin. J Laryngol Otol 111:839–844PubMedCrossRefGoogle Scholar
  124. 124.
    Laskawi R, Drobik C, Schönebeck C (1998) Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 108:381–384PubMedCrossRefGoogle Scholar
  125. 125.
    von Lindern JJ, Niederhagen B, Bergé S, Hägler G, Reich RH (2000) Frey syndrome: treatment with type A botulinum toxin. Cancer 89:1659–1663CrossRefGoogle Scholar
  126. 126.
    Dulguerov P, Quinodoz D, Cosendal G, Piletta P, Lehmann W (2000) Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg 122:821–827PubMedCrossRefGoogle Scholar
  127. 127.
    Beerens AJ, Snow GB (2002) Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg 89:116–119PubMedCrossRefGoogle Scholar
  128. 128.
    Kyrmizakis DE, Pangalos A, Papadakis CE, Logothetis J, Maroudias NJ, Helidonis ES (2004) The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg 62:840–844PubMedCrossRefGoogle Scholar
  129. 129.
    de Bree R, Duyndam JE, Kuik DJ, Leemans CR (2009) Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:287–290PubMedCrossRefGoogle Scholar
  130. 130.
    Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S (2010) Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 143:214–218PubMedCrossRefGoogle Scholar
  131. 131.
    Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, Rotteveel JJ (2003) The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 113:107–111PubMedCrossRefGoogle Scholar
  132. 132.
    Jongerius PH, Rotteveel JJ, van den Hoogen F, Joosten F, van Hulst K, Gabreëls FJ (2001) Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 160:509–512PubMedCrossRefGoogle Scholar
  133. 133.
    Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112:82–86PubMedCrossRefGoogle Scholar
  134. 134.
    Suskind DL, Tilton A, Suskind DL, Tilton A (2002) Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112:73–81PubMedCrossRefGoogle Scholar
  135. 135.
    Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreëls FJ, van Hulst K, van den Hoogen FJ (2004) Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 63:1371–1375PubMedCrossRefGoogle Scholar
  136. 136.
    Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreëls FJ, van Hulst K, Rotteveel JJ (2004) Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114:620–627PubMedCrossRefGoogle Scholar
  137. 137.
    Savarese R, Diamond M, Elovic E, Millis SR (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83:304–311PubMedCrossRefGoogle Scholar
  138. 138.
    Banerjee KJ, Glasson C, O’Flaherty SJ (2006) Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol 48:883–887PubMedCrossRefGoogle Scholar
  139. 139.
    Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough D (2008) Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol 50:123–128PubMedGoogle Scholar
  140. 140.
    Wilken B, Aslami B, Backes H (2008) Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 39:200–204PubMedCrossRefGoogle Scholar
  141. 141.
    Alrefai AH, Aburahma SK, Khader YS (2009) Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo-controlled trial. Clin Neurol Neurosurg 111:79–82PubMedCrossRefGoogle Scholar
  142. 142.
    Ong LC, Wong SW, Hamid HA (2009) Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of botulinum toxin A. J Pediatr Neurol 7:141–145Google Scholar
  143. 143.
    Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ (2010) Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 136:873–877PubMedCrossRefGoogle Scholar
  144. 144.
    Sriskandan N, Moody A, Howlett DC (2010) Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. Br J Oral Maxillofac Surg 48:58–60PubMedCrossRefGoogle Scholar
  145. 145.
    Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC (2011) Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol [Epub ahead of print]Google Scholar
  146. 146.
    Reddihough D, Graham HK (2011) Botulinum toxin type B for sialorrhea in children with cerebral palsy. Dev Med Child Neurol 53:488–489PubMedCrossRefGoogle Scholar
  147. 147.
    Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D (2011) Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 53:559–564PubMedCrossRefGoogle Scholar
  148. 148.
    Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH (2010) Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol 17(Suppl 2):109–121PubMedCrossRefGoogle Scholar
  149. 149.
    Bothwell JE, Clarke K, Dooley JM, Gordon KE, Anderson R, Wood EP et al (2002) Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 27:18–22PubMedCrossRefGoogle Scholar
  150. 150.
    Hassin-Baer S, Scheuer E, Buchman AS, Jacobson I, Ben-Zeev B (2005) Botulinum toxin injections for children with excessive drooling. J Child Neurol 20:120–123PubMedCrossRefGoogle Scholar
  151. 151.
    Pal PK, Calne DB, Calne S, Tsui JK (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54:244–247PubMedCrossRefGoogle Scholar
  152. 152.
    Friedman A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35(Suppl 3):23–27PubMedGoogle Scholar
  153. 153.
    Carod Artal FJ (2003) Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands. Neurologia 18:280–284PubMedGoogle Scholar
  154. 154.
    Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106:93–96PubMedCrossRefGoogle Scholar
  155. 155.
    Porta M, Gamba M, Bertacchi G, Vaj P (2001) Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70:538–540PubMedCrossRefGoogle Scholar
  156. 156.
    Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454–457PubMedCrossRefGoogle Scholar
  157. 157.
    Bhatia KP, Münchau A, Brown P (1999) Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 67:697PubMedCrossRefGoogle Scholar
  158. 158.
    Glickman S, Deaney CN (2001) Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 8:567–571PubMedCrossRefGoogle Scholar
  159. 159.
    Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61:1279–1281PubMedCrossRefGoogle Scholar
  160. 160.
    Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688PubMedCrossRefGoogle Scholar
  161. 161.
    Tan EK, Lo YL, Seah A, Auchus AP (2001) Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 190:95–97PubMedCrossRefGoogle Scholar
  162. 162.
    Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I et al (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69:121–123PubMedCrossRefGoogle Scholar
  163. 163.
    Manrique D (2005) Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Rev Bras Otorrinolaringol 71:556–559CrossRefGoogle Scholar
  164. 164.
    Verma A, Steele J (2006) Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 34:235–237PubMedCrossRefGoogle Scholar
  165. 165.
    Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A et al (2007) Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson’s disease. Parkinsonism Relat Disord 13:299–303PubMedCrossRefGoogle Scholar
  166. 166.
    Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M (2008) Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 255:545–550PubMedCrossRefGoogle Scholar
  167. 167.
    Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB et al (2009) Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 39:137–143PubMedCrossRefGoogle Scholar
  168. 168.
    Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J (2010) Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 207:593–597CrossRefGoogle Scholar
  169. 169.
    Ellies M, Laskawi R, Rohrbach-Volland S, Rödel R, Beuche W (2001) Blocking secretion of exocrine glands in the head-neck area by administration of botulinum toxin A. Therapy of a rare disease picture. HNO 49:807–813PubMedCrossRefGoogle Scholar
  170. 170.
    Guntinas-Lichius O, Eckel HE (2002) Temporary reduction of salivation in laryngectomy patients with pharyngocutaneous fistulas by botulinum toxin A injection. Laryngoscope 112:187–189PubMedCrossRefGoogle Scholar
  171. 171.
    Ellies M, Rohrbach-Volland S, Arglebe C, Wilken B, Laskawi R, Hanefeld F (2002) Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatrics 33:327–330PubMedCrossRefGoogle Scholar
  172. 172.
    Saberi FA, Schade H, Dressler D (2008) Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon’s duct occlusion. Toxicon 51(Suppl 1):44Google Scholar
  173. 173.
    Wabbels B, Förl M (2007) Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction. Ophthalmologe 104:771–776PubMedCrossRefGoogle Scholar
  174. 174.
    Hofmann RJ (2000) Treatment of Frey’s syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg 16:289–291PubMedCrossRefGoogle Scholar
  175. 175.
    Barañano DE, Miller NR (2004) Long-term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol 88:588–589PubMedCrossRefGoogle Scholar
  176. 176.
    Kizkin S, Doganay S, Ozisik HI, Ozcan C (2005) Crocodile tears syndrome: botulinum toxin treatment under EMG guidance. Funct Neurol 20:35–37PubMedGoogle Scholar
  177. 177.
    Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J (1998) Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 65:111–114PubMedCrossRefGoogle Scholar
  178. 178.
    Keegan DJ, Geerling G, Lee JP, Blake G, Collin JR, Plant GT (2002) Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 86:43–46PubMedCrossRefGoogle Scholar
  179. 179.
    Montoya FJ, Riddell CE, Caesar R, Hague S (2002) Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 16:705–709CrossRefGoogle Scholar
  180. 180.
    Kahle W, Leonhardt H, Platzer W (1979) Taschenatlas der Anatomie für Studium und Praxis. Band 3: Nervensystem und Sinnesorgane. 3., überarbeitete Auflage. Thieme-Verlag, StuttgartGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Movement Disorders Section, Department of NeurologyHannover Medical SchoolHannoverGermany

Personalised recommendations